<DOC>
	<DOCNO>NCT00737672</DOCNO>
	<brief_summary>The objective study establish efficacy safety GORE VIABAHN速 Endoprosthesis PROPATEN Bioactive Surface use revise arteriovenous ( AV ) prosthetic graft venous anastomosis maintenance re-establishment vascular access hemodialysis .</brief_summary>
	<brief_title>GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty ( PTA ) Revise AV Grafts Hemodialysis</brief_title>
	<detailed_description>The primary effectiveness hypothesis demonstrate GORE VIABAHN速 Endoprosthesis PROPATEN Bioactive Surface extend period target lesion primary patency compare PTA . The primary safety hypothesis demonstrate proportion subject remain free major device , procedure , treatment site-related adverse event 30 day post-procedure GORE速 VIABAHN速 Device group inferior PTA group .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Hemodialysis patient dysfunctional thrombose forearm upper arm prosthetic vascular access graft . The target lesion start less equal 30 mm venous anastomosis . The target lesion &gt; 50 % stenosis measure per protocol . The patient maximum one secondary stenosis . The age hemodialysis access graft less equal 30 day old date study procedure . The patient undergone intervention ( surgical percutaneous ) vascular access circuit less equal 30 day date study procedure . The secondary lesion occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Stent Graft</keyword>
	<keyword>Venous Anastomosis</keyword>
	<keyword>Arteriovenous Grafts</keyword>
</DOC>